National Academies Press: OpenBook
« Previous: 8 Supporting MCM Development Across Threats and Funding Cycles
Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×

A

References

Anthony, S. J., J. H. Epstein, K. A. Murray, I. Navarrete-Macias, C. M. Zambrana-Torrelio, A. Solovyov, R. Ojeda-Flores, N. C. Arrigo, A. Islam, S. Ali Khan, P. Hosseini, T. L. Bogich, K. J. Olival, M. D. Sanchez-Leon, W. B. Karesh, T. Goldstein, S. P. Luby, S. S. Morse, J. A. Mazet, P. Daszak, and W. I. Lipkin. 2013. A strategy to estimate unknown viral diversity in mammals. MBio 4(5):e00598-e00613.

Butler, D. 2015. How to beat the next Ebola. Nature (524):22-25.

Gates, B. 2015. The next epidemic: Lessons from Ebola. New England Journal of Medicine 372:1381-1384.

Ge, X. Y., J. L. Lin, X. L. Yang, A. A. Chmura, G. Zhu, J. H. Epstein, et al. 2013. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature (503):535–538. http://dx.doi.org/10.1038/nature12711.

Gire, S. K., A. Goba, K. G. Andersen, R. S. Sealfon, D. J. Park, L. Kanneh, S. Jalloh, M. Momoh, M. Fullah, G. Dudas, S. Wohl, L. M. Moses, N. L. Yozwiak, S. Winnicki, S. B. Matranga, C. M. Malboeuf, J. Qu, A. D. Gladden, S. F. Schaffner, X. Yang, P. P. Jiang, M. Nekoui, A. Colubri, M. R. Coomber, M. Fonnie, A. Moigboi, M. Gbakie, F. K. Kamara, V. Tucker, E. Konuwa, S. Saffa, J. Sellu, A. A. Jalloh, A. Kovoma, J. Koninga, I. Mustapha, K. Kargbo, M. Foday, M. Yillah, F. Kanneh, W. Robert, J. L. Massally, S. B. Chapman, J. Bochicchio, C. Murphy, C. Nusbaum, S. Young, B. W. Birren, D. S. Grant, J. S. Scheiffelin, E. S. Lander, C. Happi, S. M. Gevao, A. Gnirke, A. Rambaut, R. F. Garry, S. H. Khan, and P. C. Sabeti. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345(6202):1369-1372.

Jones, K. E., N. G. Patel, M. A. Levy, A. Storeygard, D. Balk, J. L. Gittleman, and P. Daszak. 2008. Global trends in emerging infectious diseases. Nature 451(7181):990-993.

Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×

Kinch, M. S., E. Patridge, M. Plummer, and D. Hoyer. 2014. An analysis of FDA-approved drugs for infectious disease: Antibacterial agents. Drug Discovery Today 19(9):1283-1287.

Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, H. Wang, G. Crameri, Z. Hu, H. Zhang, J. Zhang, J. McEachern, H. Field, P. Daszak, B. T. Eaton, S. Zhang, and L. F. Wang. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310(5748):676-679.

Matheny, J., M. Mair, A. Mulcahy, and B. T. Smith. 2007. Incentives for Biodefense Countermeasure Development. Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science 5:228-238.

Maurice, J. 2015. Too many unknowns stymie response to MERS. World Report. Lancet. http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)61186-2.pdf (accessed July 29, 2015).

Memish, Z. A., N. Mishra, K. J. Olival, S. F. Fagbo, V. Kapoor, J. H. Epstein, R. Alhakeem, A. Durosinloun, M. Al Asmari, A. Islam, A. Kapoor, T. Briese, P. Daszak, A. A. Al Rabeeah, and W. I. Lipkin. 2013. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerging Infectious Diseases 19(11):1819-1823.

Nolan, T., S. Roy-Ghanta, M. Montellano, L. Weckx, R. Ulloa-Gutierrez, E. Lazcano-Ponce, A. Kerdpanich, M. A. Safadi, A. Cruz-Valdez, S. Litao, F. S. Lim, A. M. de Los Santos, M. A. Weber, J. C. Tinoco, M. H. Mezerville, I. Faingezicht, P. Kosuwon, P. Lopez, C. Borja-Tabora, P. Li, S. Durviaux, L. Fries, G. Dubin, T. Breuer, B. L. Innis, and D. W. Vaughn. 2014. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. Journal of Infectious Diseases 210(4):545-557.

Osterholm, M. T., N. S. Kelley, A. Sommer, and E. A. Belongia. 2012. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infectious Diseases 12(1):36-44.

PCAST (President’s Council of Advisors on Science and Technology). 2010. Report to the president on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza. https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf (accessed June 30, 2015).

Porter, M. E., and M. R. Kramer. 2011. Creating Shared Value. Harvard Business Review January-February issue. https://hbr.org/2011/01/the-big-idea-creating-shared-value (accessed June 30, 2015).

Schieffelin, J. S., J. G. Shaffer, A. Goba, M. Gbakie, S. K. Gire, A. Colubri, R. S. Sealfon, L. Kanneh, A. Moigboi, M. Momoh, M. Fullah, L. M. Moses, B. L. Brown, K. G. Andersen, S. Winnicki, S. F. Schaffner, D. J. Park, N. L. Yozwiak, P. P. Jiang, D. Kargbo, S. Jalloh, M. Fonnie, V. Sinnah, I. French, A. Kovoma, F. K. Kamara, V. Tucker, E. Konuwa, J. Sellu, I. Mustapha, M. Foday, M. Yillah, F. Kanneh, S. Saffa, J. L. Massally, M. L. Boisen, L. M. Branco, M. A. Vandi, D. S. Grant, C. Happi, S. M. Gevao, T. E. Fletcher, R. A. Fowler,

Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×

    D. G. Bausch, P. C. Sabeti, S. H. Khan, and R. F. Garry; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. New England Journal of Medicine 371(22):2092-2100.

Sertkaya, A., J. Eyraud, A. Birkenbach, C. Franz, N. Ackerley, V. Overton, and K. Outterson. 2014. Analytical framework for examining the value of antibacterial products. http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm (accessed June 30, 2015).

Sharma, P., and A. Towse. 2011. New drugs to tackle antimicrobial resistance: Analysis of EU policy options. https://www.ohe.org/publications/new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options (accessed June 30, 2015).

Spellberg, B., P. Sharma, and J. H. Rex. 2012. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nature Reviews Drug Discovery 11(2):168.

Trock, S. C., S. A. Burke, and N. J. Cox. 2012. Development of an influenza virologic risk assessment tool. Avian Diseases 56(4 Suppl):1058-1061.

Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×

This page intentionally left blank.

Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×
Page 105
Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×
Page 106
Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×
Page 107
Suggested Citation:"A References." National Academies of Sciences, Engineering, and Medicine. 2016. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/21809.
×
Page 108
Next: B Acronyms and Abbreviations »
Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary Get This Book
×
Buy Paperback | $50.00 Buy Ebook | $39.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Emerging infectious disease threats that may not have available treatments or vaccines can directly affect the security of the world's health since these diseases also know no boundaries and will easily cross borders. Sustaining public and private investment in the development of medical countermeasures (MCMs) before an emerging infectious disease becomes a public health emergency in the United States has been extremely challenging. Interest and momentum peak during a crisis and wane between events, and there is little interest in disease threats outside the United States until they impact people stateside.

On March 26 and 27, 2015, the Institute of Medicine convened a workshop in Washington, DC to discuss how to achieve rapid and nimble MCM capability for new and emerging threats. Public- and private-sector stakeholders examined recent efforts to prepare for and respond to outbreaks of Ebola Virus Disease, pandemic influenza, and coronaviruses from policy, budget, and operational standpoints. Participants discussed the need for rapid access to MCM to ensure national security and considered strategies and business models that could enhance stakeholder interest and investment in sustainable response capabilities. This report summarizes the presentations and discussions from this workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!